Pagibaximab
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric (mouse/human) |
Target | staphylococcal lipoteichoic acid |
Clinical data | |
ATC code | none |
Identifiers | |
CAS Number | 595566-61-3 |
ChemSpider | none |
Chemical and physical data | |
Formula | C6462H9996N1728O2028S54 |
Molar mass | 146,072.36 g·mol−1 |
(what is this?) (verify) |
Pagibaximab is a chimeric monoclonal antibody for the prevention of staphylococcal sepsis in infants with low birth weight. As of March 2010, it is undergoing Phase II/III clinical trials.[1][2]
References
- ↑ Weisman, LE; Thackray, HM; Garcia-Prats, JA; Nesin, M; Schneider, JH; Fretz, J; Kokai-Kun, JF; Mond, JJ; Kramer, WG (2009). "Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates". Antimicrobial Agents and Chemotherapy. 53 (7): 2879–86. doi:10.1128/AAC.01565-08. PMC 2704668. PMID 19380597.
- ↑ Clinical trial number NCT00646399 for "Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis" at ClinicalTrials.gov
This article is issued from Wikipedia - version of the 10/25/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.